Small but agile Provista Diagnostics operates with a lean team but a CLIA/CAP certified lab in Alpharetta, GA, enabling nimble pilots and rapid deployment of diagnostic services such as PCR testing for multiple conditions. Sales opportunities: offer scalable lab partnership models, contract development, and shared-cost pilot programs to expand test menus and geographic reach.

Videssa focus Core differentiator is Videssa breast cancer blood test and related women's health diagnostics, with ongoing commercialization potential. Sales strategy: position Videssa as a cornerstone product for partnerships with clinics, cancer centers, and payer programs, and explore co-development or white-label arrangements for adjacent breast/gynecologic biomarkers.

COVID to care Diversified infectious disease testing portfolio including COVID PCR, urinary tract infections, wounds, and respiratory pathogens, funded by profits from COVID testing to reinvest in diagnostic solutions. Sales angle: offer bundled infectious disease panels, cross-sell to existing hospital laboratories, and propose integrated point-of-care or at-home testing collaborations.

Growth potential Funding history shows substantial backing ($35M) and revenue in the low-to-mid seven-figure range, with strategic interest evidenced by past acquisition activity. Sales plays: pursue channel partnerships with larger diagnostics distributors, seek co-marketing arrangements, and leverage investor visibility to open discussions with mid-market health systems.

Market position Focused on women's health diagnostics within a broader biotech landscape with established peers and potential for scale through partnerships. Sales objective: map unmet needs in women's cancer screening pathways, propose integrated testing solutions for clinics and labs, and highlight the value of fast, reliable PCR and blood-based tests to drive early detection adoption.